Benjamin Lindner

Title: Benjamin Lindner: Innovator in Cancer Detection

Introduction

Benjamin Lindner is a notable inventor based in Laupheim, Germany. He has made significant contributions to the field of cancer detection through his innovative research and patented technologies. His work focuses on the development of methods for identifying certain cancers, particularly ovarian cancer, using epigenetic markers.

Latest Patents

Lindner holds a patent titled "Epigenetic markers and related methods and means for the detection and management of certain cancers." This invention relates to methods for determining the presence or absence of specific cancers in individuals. It utilizes the detection of methylated or unmethylated CpGs associated with differentially methylated regions (DMRs) in cell-free DNA. The methods developed by Lindner have diagnostic, prognostic, and predictive utility for managing cancers, especially in women.

Career Highlights

Throughout his career, Benjamin Lindner has worked with prominent companies in the biotechnology sector. He has been associated with Eurofins Genomics Europe Sequencing GmbH and Genedata AG, where he has contributed to advancements in genomic sequencing and data analysis. His expertise in these areas has positioned him as a valuable asset in cancer research.

Collaborations

Lindner has collaborated with esteemed colleagues in the field, including Martin Widschwendter and Allison Jones. These partnerships have fostered innovation and have been instrumental in advancing research related to cancer detection and management.

Conclusion

Benjamin Lindner's contributions to cancer detection through his patented methods highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in cancer diagnostics and treatment strategies.